Llamas and COVID-19

Llama-derived Nanobodies show great potential against the SARS-Cov-2 coronavirus, confirming their status as one of Belgium’s finest biotech platform discoveries. Together with VIB – Ghent University, VIB Discovery Sciences, and several experts worldwide, 2 Bridge had the pleasure to contribute to paving an accelerated regulatory path, outlining expedited preclinical, CMC and clinical development plans. We look forward to seeing this COVID19 asset in clinical trials soon, and are eager to continue contributing to the various aspects of this global emergency.

Read all about this SARS-Cov-2 Nanobody in The New York Times and the high-impact scientific journal Cell: